Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 7 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Shanghai Hengrui Pharmaceutical Co., Ltd. is managing 12 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 12 distinct examiners, resulting in a unique examiner for every pending matter. The portfolio is active across 7 distinct art units, which suggests a broad range of technical focuses within the pharmaceutical sector.
Lee E. Sanderson is the busiest examiner for the company, currently overseeing 1 pending office action. The 12 pending office actions are each handled by a different examiner, necessitating a broad range of examiner-specific strategies. This spread across 7 distinct art units indicates that the company's research covers a wide technical range, requiring expertise from multiple specialized examination groups.
For practitioners, the 12 pending office actions represent 12 independent negotiations. Because these are spread across 7 distinct art units, the company must account for the different examination cultures and standards prevalent in each unit. Coordinating 12 distinct examiners requires a high level of oversight to maintain consistency across the Biotechnology & Pharmaceuticals portfolio while addressing 12 separate examiner perspectives.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (25%) |
| Double-patenting only | 2 (17%) |
| Double-patenting + other | 4 (33%) |
| Multi-statute (no §101) | 2 (17%) |
| No statute on record | 1 (8%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SANDERSON, LEE E | 1 | 45.4% | +44.6% |
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.2% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
| SKOKO III, JOHN JOSEPH | 1 | 53.1% | +58.2% |
| FAUST, AMBER KATHLEEN | 1 | 60.6% | +53.3% |
| BELYAVSKYI, MICHAIL A | 1 | 64.2% | +27.6% |
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682647 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | NESTOR, DONNA MICHELLE | — |
| 18284009 | TRUNCATED TACI POLYPEPTIDE AND FUSION PROTEIN AND USE THEREOF | BRISTOL, LYNN ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284654 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | BORALSKY, LUKE ALAN | 14d |
| 18772865 | METHOD FOR PREPARING BENZOFURAN DERIVATIVE | SANDERSON, LEE E | — |
| 18721934 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | RAO, PADMAJA S | — |
| 18703712 | NITROGEN-CONTAINING TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SZNAIDMAN, MARCOS L | — |
| 18694365 | ANTI-KLB ANTIBODIES AND USES | ALLEN, MARIANNE P | — |
| 18682647 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | NESTOR, DONNA MICHELLE | — |
| 18580602 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TROP2 ANTIBODY DRUG CONJUGATE AND ITS APPLICATION | SKOKO III, JOHN JOSEPH | — |
| 18580328 | PHARMACEUTICAL COMPOSITION OF ANTI-ANGPTL3 ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF AND ITS APPLICATION | FAUST, AMBER KATHLEEN | — |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| 1627 | 1 |
| 1644 | 1 |
| 1624 | 1 |
| 1643 | 1 |
| 1646 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18772865 | METHOD FOR PREPARING BENZOFURAN DERIVATIVE | SANDERSON, LEE E | 3991 | Other | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18721934 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | RAO, PADMAJA S | — | §102§103§112DPOther | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18703712 | NITROGEN-CONTAINING TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SZNAIDMAN, MARCOS L | — | §112 | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18694365 | ANTI-KLB ANTIBODIES AND USES | ALLEN, MARIANNE P | — | §112 | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18682647 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | NESTOR, DONNA MICHELLE | 1627 | §103§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18580602 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TROP2 ANTIBODY DRUG CONJUGATE AND ITS APPLICATION | SKOKO III, JOHN JOSEPH | — | §112DP | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18580328 | PHARMACEUTICAL COMPOSITION OF ANTI-ANGPTL3 ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF AND ITS APPLICATION | FAUST, AMBER KATHLEEN | — | §102§103DP | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18290132 | ANTIGEN BINDING MOLECULE SPECIFICALLY BINDING TO RANKL AND NGF, AND MEDICAL USE THEREOF | BELYAVSKYI, MICHAIL A | 1644 | §103§112DP | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18284654 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | BORALSKY, LUKE ALAN | 1624 | §112 | Final Rejection | 14d | Pending | Sep 28, 2023 |
| 18284009 | TRUNCATED TACI POLYPEPTIDE AND FUSION PROTEIN AND USE THEREOF | BRISTOL, LYNN ANNE | 1643 | §102§103§112Other | Non-Final OA | — | Pending | Sep 25, 2023 |
| 17793005 | ANTI-TROP-2 ANTIBODY-EXATECAN ANALOG CONJUGATE AND MEDICAL USE THEREOF | PUTTLITZ, KARL J | 1646 | DP | Final Rejection | 2d overdue | Pending | Jul 14, 2022 |
| 17782980 | ANTI-CLAUDIN ANTIBODY-DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | HUYNH, PHUONG N | 1641 | DP | Non-Final OA | — | Pending | Jun 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial